Program
apixaban
Also written as “Apixaban”, “Apixaban 5 MG” and “Apixaban 5 mg Oral Tablet”.
Its studies are mostly in Venous Thrombosis · Atrial Fibrillation · Thrombosis · Acute Coronary Syndrome · Venous Thromboembolism, led by 7 companies.
Drug pageApixaban: every studyMany companies study it; this page follows only the 37 they lead. All 179 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibbits history only | 260 open or running | phase 4since Jun 6, 2013 | Nov 22, 2004 | none ahead |
| Pfizerits history only | 60 open or running | phase 4since Feb 5, 2014 | Nov 5, 2008 | none ahead |
| Artivion | 10 open or running | phase 3since Oct 9, 2019 | Oct 9, 2019 | none ahead |
| Dexa Medica Groupits history only | 10 open or running | phase 1since Feb 5, 2025 | Feb 5, 2025 | none ahead |
| Humanis Saglık Anonim Sirketiits history only | 10 open or running | phase 1since Sep 4, 2023 | Sep 4, 2023 | none ahead |
| Scotmann Pharmaceuticalsits history only | 10 open or running | phase 2since Oct 21, 2021 | Oct 21, 2021 | none ahead |
| TAHO Pharmaceuticalsits history only | 10 open or running | early phase 1since Jul 24, 2023 | Jul 24, 2023 | none ahead |
Also a collaborator on its studies: Link Medical Research AB, Parexel and PT Equilab International.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Artivion only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 9, 2019First study: phase 3 study in Aortic Valve DiseaseFirst studyNCT04142658 · 863 enrolled · United States
TargetBeta
“Coagulation factor X inhibitor”ChEMBL 37, by rule
Other programs on F10
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Rivaroxabanrule | Bayer | phase 4 | 77 |
| emicizumabrule | Hoffmann-La Roche | phase 4 | 13 |
| Factor Xrule | kedrion-s-p-a | phase 3 | 1 |
Studies
The one study Artivion leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04142658Aortic Valve Disease · United States | 3 | Terminated | Dec 12, 2022 | 863 |
How it is read
Names in the registry
- “Apixaban”, 38 entries
- “Apixaban 5 MG”, 2 entries
- “apixaban”, 2 entries
- “Apixaban 5 mg Oral Tablet”, 1 entry
- “Apixaban 5MG”, 1 entry
Conditions, from the studies’ own filings
- Venous Thrombosis, 7 studies
- Atrial Fibrillation, 6 studies
- Thrombosis, 4 studies
- Acute Coronary Syndrome, 4 studies
- Venous Thromboembolism, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.